Stock Events

Stock Events

ABVC BioPharma 

$1
0
+$0.1+11.18% Today

Statistics

Day High
1
Day Low
1
52W High
-
52W Low
-
Volume
1,642
Avg. Volume
-
Mkt Cap
24.19M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Oct 13
$83,856.98
Mar 13
$71.08
Jan 13
$113,775.64
Oct 12
$59,091.82
Aug 12
$7,025.73
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

19MayExpected
Q4 2023
Q2 2025
Q4 2025
Next
-0.5
-0.17
0.17
0.5
Expected EPS
N/A
Actual EPS
N/A

Financials

-961.37%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
1.02MRevenue
-9.81MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ABVC.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on neurodegenerative diseases, similar to ABVC BioPharma's interest in psychiatric and neurological disorders.
Alkermes
ALKS
Mkt Cap5.07B
Alkermes works on central nervous system (CNS) diseases, aligning with ABVC's research in psychiatric and neurological conditions.
AMGEN
AMGN
Mkt Cap160.66B
Amgen has a broad portfolio that includes treatments for neurological disorders, competing in the same therapeutic area as ABVC.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly has a strong focus on Alzheimer's disease, which is a key area of research for ABVC BioPharma.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a diversified portfolio that includes CNS treatments, making it a competitor in ABVC's market space.
Merck
MRK
Mkt Cap214.76B
Merck is involved in developing therapies for Alzheimer's disease, directly competing with ABVC's research interests.
Novartis
NVS
Mkt Cap237.61B
Novartis has a significant presence in neuroscience, including treatments for neurological conditions that ABVC also targets.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its Janssen Pharmaceuticals division, competes in the neurology and psychiatry sectors.
Rogers
ROG
Mkt Cap1.57B
Roche, with its strong focus on neuroscience and Alzheimer's disease research, competes in similar therapeutic areas as ABVC.

About

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Show more...
CEO
ISIN
US00091F3047

Listings

XNAS
US
ABVC
BOATS
BOATS
ABVC.BOATS

0 Comments

Share your thoughts

FAQ

What is ABVC BioPharma stock price today?▼
The current price of ABVC.BOATS is $1 USD — it has increased by +11.18% in the past 24 hours. Watch ABVC BioPharma stock price performance more closely on the chart.
What is ABVC BioPharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange ABVC BioPharma stocks are traded under the ticker ABVC.BOATS.
What is ABVC BioPharma market cap?▼
Today ABVC BioPharma has the market capitalization of 24.19M
When is the next ABVC BioPharma earnings date?▼
ABVC BioPharma is going to release the next earnings report on May 19, 2026.
What is ABVC BioPharma revenue for the last year?▼
ABVC BioPharma revenue for the last year amounts to 1.02M USD.
What is ABVC BioPharma net income for the last year?▼
ABVC.BOATS net income for the last year is -9.81M USD.
Does ABVC BioPharma pay dividends?▼
Yes, ABVC.BOATS dividends are paid quarterly. The last dividend per share was 83,856.98 USD. As of today, Dividend Yield (FWD)% is 0%.
When did ABVC BioPharma complete a stock split?▼
ABVC BioPharma has not had any recent stock splits.